{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:53:12Z","timestamp":1722930792762},"reference-count":18,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NIH\/NIDCR\/NIAID","award":["U01 AI 68636"],"award-info":[{"award-number":["U01 AI 68636"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Diseases"],"published-print":{"date-parts":[[2016,4]]},"abstract":"The Oral HIV<\/jats:styled-content>\/AIDS<\/jats:styled-content> Research Alliance (OHARA<\/jats:styled-content>) was established in 2006 to provide the capacity to investigate the oral complications associated with HIV<\/jats:styled-content>\/AIDS<\/jats:styled-content> within the ACTG<\/jats:styled-content> infrastructure. Its goals were to explore the effects of potent antiretroviral therapy (ART<\/jats:styled-content>) on the development of opportunistic infections, and variation and resistance of opportunistic pathogens in the context of immune suppression and long\u2010term ART<\/jats:styled-content>. The objectives of this talk, presented as part of a plenary session at the 7th World Workshop on Oral Health and Disease in AIDS<\/jats:styled-content>, were to (i) provide an overview of OHARA<\/jats:styled-content>'s most recent research agenda, and how it evolved since OHARA<\/jats:styled-content>'s inception; (ii) describe OHARA<\/jats:styled-content>'s main accomplishments, including examples of research protocols completed and their key findings; and (iii) describe spin\u2010off projects derived from OHARA<\/jats:styled-content>, lessons learned, and future directions.<\/jats:p>OHARA<\/jats:styled-content> has met its central goal and made key contributions to the field in several ways: (i) by developing\/updating diagnostic criteria for oral disease endpoints commonly measured in OHARA<\/jats:styled-content> protocols and in HIV<\/jats:styled-content>\/AIDS<\/jats:styled-content> research in general and has creating standardized training modules, both for measuring these oral disease endpoints across clinical specialties, and for collecting oral fluid specimens; (ii) by implementing a total of nine protocols, six of which are completed. Three protocols involved domestic research sites, while three involved international research sites (in Africa, India, and South America); (iii) and by developing and validating a number of laboratory assays used in its protocols and in the field of oral HIV<\/jats:styled-content>\/AIDS<\/jats:styled-content> research.<\/jats:p>","DOI":"10.1111\/odi.12409","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T05:31:03Z","timestamp":1461562263000},"page":"128-134","source":"Crossref","is-referenced-by-count":6,"title":["The Oral HIV\/AIDS Research Alliance Program: lessons learned and future directions"],"prefix":"10.1111","volume":"22","author":[{"given":"CH","family":"Shiboski","sequence":"first","affiliation":[{"name":"Department of Orofacial Sciences School of Dentistry University of California San Francisco San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JY","family":"Webster\u2010Cyriaque","sequence":"additional","affiliation":[{"name":"Department of Dental Ecology School of Dentistry University of North Carolina at Chapel Hill Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Department of Dermatology Center for Medical Mycology University Hospitals Case Medical Center and Case Western Reserve University Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DP","family":"Dittmer","sequence":"additional","affiliation":[{"name":"Department of Dental Ecology School of Dentistry University of North Carolina at Chapel Hill Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JS","family":"Greenspan","sequence":"additional","affiliation":[{"name":"Department of Orofacial Sciences School of Dentistry University of California San Francisco San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Oral HIV\/AIDS Research Alliance, Subcommittee of the AIDS Clinical Trial Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,4,25]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"ACTG(2015).ACTG AIDS Clinical Trials Group Network. History of the ACTG. Available at:https:\/\/actgnetwork.org\/History[accessed on 27 January 2015]."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2013.09.003"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02777-13"},{"key":"e_1_2_8_5_1","unstructured":"CranstonR YangM PaczuskiPet\u00a0al(2014).Baseline data of a phase 3 trial of the quadrivalent HPV vaccine in HIV+ males and females: ACTG 5298. 22st Conference on Retroviruses and Opportunistic Infections Boston MA."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.07.022"},{"key":"e_1_2_8_7_1","unstructured":"KojicEM CespedesM UmblejaTet\u00a0al(2012).ACTG 5240 study group safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV\u2014positive women. Women XIX International AIDS Conference Washington DC."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu238"},{"key":"e_1_2_8_9_1","unstructured":"MukherjeeP PattonL HakimJet\u00a0al(2015).A5265 clinical trial: gentian violet for oral candidiasis is as effective as nystatin. 23rd Conference on Retroviruses and Opportunistic Infections Seattle WA."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/154407370601900103"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-194"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.2009.00749.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0022034511399086"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0022034511399084"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0729"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131001"},{"key":"e_1_2_8_17_1","unstructured":"ShiboskiCH LeeA Webster\u2010CyriaqueJet\u00a0al(2015b).Oral HPV shedding and warts after starting antiretroviral therapy: ACTG protocol 5272. 23rd Conference on Retroviruses and Opportunistic Infections Seattle WA."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0737"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318215c7b1"}],"container-title":["Oral Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fodi.12409","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/odi.12409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:21:54Z","timestamp":1694553714000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/odi.12409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":18,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/odi.12409"],"URL":"https:\/\/doi.org\/10.1111\/odi.12409","archive":["Portico"],"relation":{},"ISSN":["1354-523X","1601-0825"],"issn-type":[{"type":"print","value":"1354-523X"},{"type":"electronic","value":"1601-0825"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}